



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سلوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد



CLINICAL OUTCOMES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA HARBORING IDH1 MUTATION AFTER INTENSIVE CHEMOTHERAPY

Thesis

Submitted for Partial Fulfillment of Master Degree
In Clinical Hematology

By

John Ahdi Saweris

(M.B., B. Ch.) 2013

Faculty of Medicine - Ain Shams University

Supervised by

Prof. Dr. Mohamed Osman Azzazi

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Prof. Dr. Walaa Ali El Salakawy

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Dr. Nour El Hoda Hussien Abdalla

Lecturer of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2022 

List of Contents

Title	Page
▪ List of Abbreviations.....	I
▪ List of Tables.....	III
▪ List of Figures	VI
▪ Introduction.....	
▪ Aim of the Work.....	
▪ Review of Literature	
- Chapter (1): Acute Myeloid Leukemia	4
- Chapter (2): Isocitrate Dehydrogenase Mutations in Myeloid Malignancies	28
▪ Patients and Methods	58
▪ Results	74
▪ Discussion	89
▪ Summary.....	99
▪ Conclusion	
▪ References.....	
▪ Arabic Summary.....	--

List of Abbreviations

Abb.	Full term
▪ 2HGD.....	▪ 2-hydroxyglutarate dehydrogenases
▪ AML.....	▪ Acute myeloid leukemia
▪ APL	▪ Acute promyelocytic leukemia
▪ ASXL1	▪ Additional sex comb-like 1 mutations
▪ ATO	▪ Arsenic trioxide
▪ ATRA.....	▪ All-trans retinoic acid
▪ CBFA2	▪ Core-binding factor subunit-2
▪ CBFB	▪ Core binding factor beta subunit
▪ CD.....	▪ Common differentiation
▪ CEBPA....	▪ Ccaat enhancer binding protein
▪ CIBMTR .	▪ Center of international blood and marrow transplant research
▪ CN-AML.	▪ Cytogenetically normal
▪ CR	▪ Complete remission
▪ DFS	▪ Disease free survival
▪ DIC.....	▪ Disseminated intravascular coagulation
▪ DNMT3A	▪ Dna methyltransferase 3a mutations
▪ ELN.....	▪ European leukemianet
▪ EVI1	▪ Ecotropic virus integration site 1
▪ FAB.....	▪ French-american- british classification
▪ FLT3	▪ Fms-like tyrosine kinase 3 mutations
▪ HLADR...	▪ Human leukocyte antigen-antigen d related
▪ HMAs.....	▪ Hypomethylating agents
▪ HRM	▪ High resolution melt

▪ HSCT	▪ Hematopoietic stem cell transplantation
▪ IDHs	▪ Isocitrate dehydrogenases
▪ ITD	▪ Internal tandem duplications
▪ JAK2	▪ The janus kinase 2 gene
▪ JM	▪ Juxta-membrane
▪ L-2HG	▪ L-2-hydroxyglutarate enantiomer
▪ MDS	▪ Myelodysplastic syndrome
▪ MLL	▪ Mixed lineage leukemia
▪ MPD	▪ Myeloid proliferative disorder
▪ MPL	▪ Myeloproliferative leukemia
▪ MRD	▪ Minimal residual leukemia
▪ MYH11 ...	▪ Smooth muscle myosin heavy chain 11
▪ NADPH...	▪ Nicotinamide adenine dinucleotide phosphate
▪ NGS	▪ Next generation sequencing
▪ NPM1	▪ Nucleophosmin 1
▪ OS	▪ Overall survival
▪ PCR	▪ Polymerase chain reaction
▪ PHDs	▪ Prolyl hydroxylases
▪ PML- RARA	▪ Promyelocytic leukemia/retinoic acid receptor alpha
▪ PTD	▪ Partial in tandem duplications
▪ RUNX1 ...	▪ Runt-related transcription factor
▪ RUNX1T1	▪ Runx1 partner transcriptional co-repressor 1
▪ SRSF2	▪ Serine/ arginine-rich- splicing-factor-2 gene
▪ t-AML	▪ Therapy-related aml
▪ TdT	▪ Terminal deoxynucleotidyl transferase

- TET2 ▪ Ten–eleven translocation 2
- TKD ▪ Tyrosine kinase domain
- TKI..... ▪ Tyrosine kinase inhibitors
- UK NCRC ▪ United kingdom national cancer research
institute
- WT1 ▪ Wilms‘ tumor 1 gene
- α -KG ▪ A-ketoglutarate

List of Tables

Table No.	Title	Page
Table (1):	ELN risk stratification of molecular, genetic and cytogenetic alterations	15
Table (2):	Summary of frequencies of IDH1 and IDH2 mutations in adult and pediatric patients	37
Table (3):	Frequencies of common recurrent gene mutations in adults with AML or MDS	39
Table (4):	Demographic data for all the studied patients.....	75
Table (5):	The mean age was 40.93±12.75 SD with range (19-60)	75
Table (6):	FAB Classification of all studied patients.....	76
Table (7):	Clinical and laboratory characteristics of the studied patients.....	77
Table (8):	Clinical and laboratory characteristics of the studied patients.....	77
Table (9):	Risk classification according to cytogenetics and IDH1 mutation in all studied patients.....	78
Table (10):	Chemotherapy protocols & Response and 6 months outcome in all studied patients.....	79

List of Tables (Continued)

Table No.	Title	Page
Table (11):	Chemotherapy protocols & Response and 6 months outcome in all studied patients.....	80
Table (12):	Association between IDH1 mutation and demographic data for all the studied patients	81
Table (13):	Chemotherapy protocols & Response and 6 months outcome in all studied patients.....	81
Table (14):	Association between IDH1 mutation and FAB Classification of all studied patients.....	81
Table (15):	Association between IDH1 mutation and clinical and laboratory characteristics of the studied patients.....	82
Table (16):	Association between IDH1 mutation and FAB Classification of all studied patients.....	82
Table (17):	Association between IDH1 mutation and Risk classification according to cytogenetics in all studied patients	83
Table (18):	Association between IDH1 mutation and Chemotherapy protocols & Response and 6 months outcome in all studied patients.....	83

List of Tables (Continued)

Table No.	Title	Page
Table (19):	Association between IDH1 mutation and FAB Classification of all studied patients.....	19
Table (20):	Mean survival as regard time to complete remission and lines of chemotherapy	85
Table (21):	Mean survival as regard time to death and lines of chemotherapy	86
Table (22):	Mean survival as regard time to complete remission and IDH1 mutation	87
Table (23):	Mean survival as regard time to death and IDH1 mutation.....	88

List of Figures

Figure No.	Title	Page
Fig. (1):	IDH mutations in cancer	29
Fig. (2):	Location of IDH2 mutation may influence prognosis in AML	43
Fig. (3):	(R)-2-HG level may serve as a biomarker of prognosis and treatment effects	45
Fig. (4):	Detection of IDH mutations by Sanger sequencing	47
Fig. (5):	Two enantiomers, D-2HG and L-2HG, measured by liquid chromatography–tandem mass spectrometry	49
Fig. (6):	HRM Difference Plot	62
Fig. (7):	Software scheme for new experiment...	65
Fig. (8):	Thermal cycle steps in HRM	69
Fig. (9):	Melt Curve Tab, High Resolution Melt	72
Fig. (10):	Examples of HRM results	73
Fig. (11):	Distribution of the studied cases according to sex	75
Fig. (12):	Distribution of the studied cases according to FAB classification	76
Fig. (13):	Distribution of the studied cases according to TLC, HB and PLTs	78
Fig. (14):	Distribution of the studied cases according to TLC, HB and PLTs	80

List of Figures (Continued)

Figure No.	Title	Page
Fig. (15):	Mean survival as regard time to complete remission and lines of chemotherapy	85
Fig. (16):	Mean survival as regard time to death and lines of chemotherapy	86
Fig. (17):	Mean survival as regard time to complete remission and IDH1 mutation	87
Fig. (18):	Mean survival as regard time to death and IDH1 mutation.....	88

INTRODUCTION

Acute myeloid leukemia (AML) is heterogeneous myeloid disorder with multifactorial pathogenic mechanisms and a broad range of prognosis. AML is characterized by clonal proliferation of poorly differentiated cells of the myeloid lineage (*Dohner et al., 2015*).

The pathogenesis involve recurrent genomic alterations, including somatic gene mutations and/or chromosomal abnormalities, that can define biologically distinct clinical subtypes (*Vardiman et al., 2009*).

Comprehensive genomic profiling at the time of diagnosis can inform disease classification, risk stratification and prognosis and ultimately allow for more selective therapeutic interventions. Alterations to cellular metabolism, as well as somatic mutations of genes essential to epigenetic regulation, are implicated in the pathogenesis of several human malignancies(*Cairns et al., 2011; Conway et al., 2014*).

Isocitrate dehydrogenases (IDHs) are homodimeric enzymes involved in diverse cellular processes, including adaptation to hypoxia, histone demethylation and DNA modification(*Clark et al., 2016*).

IDH1 protein catalyze the oxidative decarboxylation of isocitrate to α -ketoglutarate (α -KG) to produce reduced nicotinamide adenine dinucleotide phosphate.

-Introduction-

Diverse dioxygenases depend on sufficient levels of α -KG for multiple cellular processes, as well as for epigenetic regulation (***Molenaar et al., 2014***).

IDH1 enzymes are localized to the cytoplasm and peroxisomes (***Clark et al., 2016***).

Somatic mutations in IDH1 (mIDH1) genes have been described in both solid and hematological malignancies (***Stein, 2016***).

IDH1 mutations are heterozygous, retaining one wild-type, suggestive of an oncogenic gain of function. IDH proteins are encoded by the IDH1 gene located at chromosome 2q33. Recurrent IDH1 mutations are missense variants leading to a single amino-acid substitution of arginine residues at codon 132 in exon 4 of the IDH1 gene. Additionally, a germline-synonymous single-nucleotide polymorphism (rs11554137) located in codon 105 in exon 4 of the IDH1 gene has been reported to have prognostic relevance in AML (***Willander et al., 2014; Wagner et al., 2010***). In our study we will provide an overview of the Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 mutation after Intensive Chemotherapy.

AIM OF THE WORK

The aim of the present study is to detect IDH1 Mutation in adult Egyptian AML patient and find correlation between the mutation and prognosis & survival in those patients after intensive chemotherapy.

Chapter (1)

Acute Myeloid Leukemia

I. Introduction

Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood. Previously incurable, AML is now cured in approximately 35%-40% of patients younger than age 60 years old. For those >60 years old, the prognosis is improving but remains grim. Studies have revealed that the disorder arises from a series of recurrent hematopoietic stem cell genetic alterations accumulated with age. Using deep sequencing techniques on primary and relapsed tumors, a phenomenon called clonal evolution has been characterized with both founding clones and novel subclones, impacting the therapeutic approach. Despite an increased understanding of AML biology, our efforts to this point in changing treatment strategy have been disappointing. In this review, we discuss the current diagnostic and prognostic strategies, current treatment approaches and novel therapies critical to AML management (*Khwaja et al., 2016*).

II. Morphology

Morphologically, AML blasts vary in size from slightly larger than lymphocytes to the size of monocytes or larger. The nuclei are large in size, varied in shape and usually contain several nucleoli. AML blasts express